Key result
Antithrombotic therapy reduces CV events in high-risk atherothrombosis but increases bleeding risk.
Why the study?
The efficacy and safety of aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes remained uncertain based on prior clinical trials.
Does low-dose aspirin reduce cardiovascular events in patients with type 2 diabetes?
Does low-dose aspirin reduce cardiovascular events in patients with type 2 diabetes?
This review highlights that while aspirin is used for primary prevention, the JPAD trial showed no significant reduction in cardiovascular events for Japanese patients with type 2 diabetes overall, though a potential benefit was seen in those aged 65 and older.
Careful selection needed to optimize antithrombotic benefit-risk; leaves open identification of ideal candidates in prospective trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Yamane et al. (2013) conducted a review in Atherothrombotic disease (ischemic heart disease, ischemic stroke). Antithrombotic therapy was evaluated. Antithrombotic therapy is effective for preventing cardiovascular events in high-risk patients with atherothrombotic disease, but requires careful patient selection to balance benefits against increased bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: